The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Incorporating CELMoDs into the induction & maintenance therapy of patients with multiple myeloma
Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, comments on the possibility of replacing lenalidomide with iberdomide or mezigdomide in the induction and maintenance therapy of patients with multiple myeloma to improve the efficacy of these strategies and to increase the duration of therapy to eventually improve patient outcomes. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
